manilatimes.net · Jun 3, 2026 03:01 UTC

ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released

Summary

BEIJING, June 02, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer a...

Original reporting

Open original source

Related coverage

Read full article on manilatimes.net